eribulin mesylate + capecitabine
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Estrogen Receptor Positive Tumor
Conditions
Estrogen Receptor Positive Tumor, Breast Cancer
Trial Timeline
Aug 1, 2011 → May 1, 2014
NCT ID
NCT01439282About eribulin mesylate + capecitabine
eribulin mesylate + capecitabine is a phase 2 stage product being developed by Eisai for Estrogen Receptor Positive Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT01439282. Target conditions include Estrogen Receptor Positive Tumor, Breast Cancer.
What happened to similar drugs?
1 of 3 similar drugs in Estrogen Receptor Positive Tumor were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01439282 | Phase 2 | Completed |
| NCT01323530 | Phase 1/2 | Completed |
| NCT00337103 | Phase 3 | Completed |
Competing Products
20 competing products in Estrogen Receptor Positive Tumor